Akcea Therapeutics gets FDA approval for Tegsedi injection
Tegsedi's approval in the United States comes nearly three months after its approval in Europe.
New Delhi: Akeda Therapeutic Inc has recently announced its treatment, developed along with Ionis Pharmaceuticals, which targets a rare genetic disease was approved by the U.S. Food and Drug Administration.
Akcea's once-weekly injection, Tegsedi, treats hereditary ATTR amyloidosis patients with polyneuropathy. Tegsedi is a medicine used to treat nerve damage caused by hereditary transthyretin amyloidosis (hATTR), a disease in which proteins called amyloids to build up in tissues around the body including around the nerves.
Polyneuropathy, a symptom of the disease, is the simultaneous malfunction of peripheral nerves in the body resulting in tingling, numbness and kidney dysfunction.
Tegsedi belongs to a class of drugs that uses the Nobel-prize winning RNA interference mechanism to manipulate ribonucleic acid, which interferes with or "silences" targeted genes and stops the formation of proteins that can cause diseases.
Tegsedi's approval in the United States comes nearly three months after its approval in Europe.
Based on the U.S. approval of Tegsedi, Ionis will receive a $50 million milestone payment and both the companies will split the gains from the drug's sale at a ratio of 60 to 40 in favour of Ionis, Akcea said.
Earlier this year, the drug regulator had declined to approve Akcea's similar drug, Waylivra, which looked to treat a genetic disease causing fat accumulation in the blood.
New Delhi: Akeda Therapeutic Inc has recently announced its treatment, developed along with Ionis Pharmaceuticals, which targets a rare genetic disease was approved by the U.S. Food and Drug Administration.
Akcea's once-weekly injection, Tegsedi, treats hereditary ATTR amyloidosis patients with polyneuropathy. Tegsedi is a medicine used to treat nerve damage caused by hereditary transthyretin amyloidosis (hATTR), a disease in which proteins called amyloids to build up in tissues around the body including around the nerves.
Polyneuropathy, a symptom of the disease, is the simultaneous malfunction of peripheral nerves in the body resulting in tingling, numbness and kidney dysfunction.
Tegsedi belongs to a class of drugs that uses the Nobel-prize winning RNA interference mechanism to manipulate ribonucleic acid, which interferes with or "silences" targeted genes and stops the formation of proteins that can cause diseases.
Tegsedi's approval in the United States comes nearly three months after its approval in Europe.
Based on the U.S. approval of Tegsedi, Ionis will receive a $50 million milestone payment and both the companies will split the gains from the drug's sale at a ratio of 60 to 40 in favour of Ionis, Akcea said.
Earlier this year, the drug regulator had declined to approve Akcea's similar drug, Waylivra, which looked to treat a genetic disease causing fat accumulation in the blood.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd